Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Pain. 2020 Oct;161(10):2364–2375. doi: 10.1097/j.pain.0000000000001924

Figure 3.

Figure 3.

NR ameliorates the loss of IENF caused by paclitaxel in both tumor-naïve and tumor-bearing rats. Upper panels are scatterplots of IENF density in individual rats obtained 14 days after initiation of paclitaxel treatment. Bars are the mean ± SEM. * P < 0.05, ** P < 0.01 for indicated comparison. Bottom panels are representative confocal images of PGP.5 immunoreactivity in the plantar skin of the hind paw of untreated, paclitaxel-treated rats that received vehicle, and paclitaxel-treated rats that received NR. Immunostaining for collagen IV is not depicted. Images are the composite maximum intensity projections of ~13 optical sections taken at 1 μm intervals. Imaging parameters and any adjustments for contrast were the same within a treatment condition. Scale bar is 100 microns.